Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

MACD Volume



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 29 13.5 0.72% 2.63% 11.0% -4.5% 195.8%
SHORT 29 12.1 0.45% 0.81% 8.7% -7.5% -5.9%


Technical Analysis

Ra Pharmaceuticals Inc (RARX)



Last Signal:


Trading: HOLD @ $46.99
Signal Strength: MEDIUM

Ra Pharmaceuticals Inc (NASDAQ:RARX) currently has positive Volume MACD of 177577. This means the signal line is greater than the Volume MACD line signalling a bullish movement.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement

Volume Moving Average Convergence/Divergence (VMACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).

Calculation: Moving Average Convergence Divergence Volume (VMACD):
1) VMACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of VMACD Line;
3) VMACD Histogram: VMACD Line - Signal Line;

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

MACD Volume

Company Close Change(%) Volume Value Signal
NVAX Novavax Inc 5.74 20.1 9,559,800 -4,081 BEARISH
MESO Mesoblast Ads 9.39 13 403,000 -72,162 BEARISH
VRAY Viewray Inc 3.12 6.8 5,344,700 -16,430 BEARISH
WING Wingstop 93.32 6.5 833,300 -56,067 BEARISH
EPZM Epizyme Inc 26.72 4.6 1,255,600 -43,894 BEARISH
ATRC Atricure Inc 38.25 4.1 790,500 -23,382 BEARISH
GBLI Global Indemnity Plc 30.7 3.2 13,100 -3,150 BEARISH
PETS Petmed Express Inc 27.26 2.8 905,900 -7,786 BEARISH
FOSL Fossil Group 8.32 2.7 965,800 -492 BEARISH
BCOM B Communications 1.61 2.5 700 -5,823 BEARISH